FINWIRES · TerminalLIVE
FINWIRES

$CTVA

13 stories mentioning CTVAUpdated 11d ago

Every FINWIRES story that references CTVA, newest first.

Wire

Corteva Q2 Adjusted Earnings Rise, Revenue Falls; Shares Drop After Hours

Corteva (CTVA) reported Q2 adjusted earnings late Thursday of $2.30 per diluted share, up from $2.20 a year earlier.Analysts polled by FactSet expected $2.24.Revenue in the three months ended June 30 fell to $6.38 billion from $6.46 billion a year earlier.Analysts expected $6.6 billion.The company raised its full-year operating EPS guidance to the range of $3.60 to $3.80 from the prior forecast of $3.45 to $3.70.Analysts project $3.76.Corteva shares fell 6% in after-hours trading.

$CTVA
Wire

Corteva Keeps Quarterly Dividend at $0.18 a Share, Payable Sept. 15 to Holders of Record Sept. 1

Corteva Keeps Quarterly Dividend at $0.18 a Share, Payable Sept. 15 to Holders of Record Sept. 1

$CTVA
Chemicals Companies Likely to Report In-Line Quarterly Results, Deutsche Bank Says
US Markets

Chemicals Companies Likely to Report In-Line Quarterly Results, Deutsche Bank Says

US chemicals companies are likely to report quarterly results in line with expectations, with the Middle East conflict seen as a potential tailwind, Deutsche Bank said Wednesday.The June quarter "largely played out" as expected in terms of demand, pricing and costs, supported by positive pre-announcements by Dow (DOW) and BASF, according to Deutsche Bank.In June, Dow Chief Financial Officer Jeff Tate said the company expected to post second-quarter earnings of about $2.2 billion, "which is above current consensus and roughly 10% above our prior guidance," according to a FactSet transcript. "This is largely driven by continued resilience in polyethylene demand and pricing, as well as margin upside in industrial intermediates and infrastructure."The company is scheduled to report its full second-quarter results Thursday.Earlier this month, German chemicals producer BASF increased its full-year core earnings outlook, citing "better-than-expected business development.""With the macro remaining uncertain, energy prices elevated due to the on-again, off-again Middle East conflict and underlying demand subdued, management teams are likely to remain cautious in their outlooks and guidance," Deutsche Bank analyst David Begleiter said in a note to clients Wednesday.The conflict between the US and Iran and the subsequent shutdown of the Strait of Hormuz -- the world's most important chokepoint for crude flows -- has been a "positive, or at least not a negative" for US chemicals firms and the wider industry of US material, industrial gas, coatings and agricultural companies, Begleiter wrote.The conflict disrupted energy and chemical production and exports from the Persian Gulf, which houses about 15% of global chemical supply, according to Deutsche Bank. The war impacted another 15% of global chemical capacity, while high oil prices increased input costs for chemical producers in Asia, the brokerage said.In the current geopolitical environment, Deutsche Bank has a favorable view on companies such as Celanese (CE), Corteva (CTVA), Ecolab (ECL), Linde (LIN) and PPG Industries (PPG), where investor sentiment is in the wrong position, there are short-term catalysts and organic growth and the companies can maintain prices when raw material costs decline, according to the note.Price: $31.38, Change: $+0.91, Percent Change: +2.99%

$CE$CTVA$DOW$ECL$LIN$PPG
Wire

3M, DuPont, Corteva, Chemours Sued by New York AG Over Toxic Pollution From Consumer Products

3M (MMM), EIDP, Chemours Co. (CC), Corteva (CTVA) and DuPont de Nemours (DD) are facing a New York State lawsuit alleging that they knowingly sold toxic polyfluoroalkyl substances -- so-called forever chemicals or PFAS -- used in a range of consumer goods.New York Attorney General Letitia James said Thursday that the chemical manufacturers produced and sold the materials despite knowing their toxicity while actively hiding environmental and health hazards from the public.Company data allegedly showed that 3M found the substances in human blood during the 1970s, while DuPont allegedly suppressed 1981 research linking the products to birth defects in exposed pregnant employees, according to the AG statement.The state is seeking a court order to establish corporate liability, force the businesses to finance environmental remediation, and secure monetary restitution alongside other penalties, the statement added.3M, EIDP, Chemours, Corteva, DuPont de Nemours did not immediately respond to' requests for comment.Price: $156.72, Change: $+2.02, Percent Change: +1.31%

$CC$CTVA$DD$MMM
Wire

Street Color: 3M, Chemours Among Firms Sued by New York Attorney General Over Alleged PFAS Pollution

Street Color: 3M, Chemours Among Firms Sued by New York Attorney General Over Alleged PFAS Pollution

$CC$CTVA$DD$MMM
Wire

Deutsche Bank Adjusts Price Target on Corteva to $100 From $90

Corteva (CTVA) has an average rating of overweight and mean price target of $88.38, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $82.86, Change: $+1.72, Percent Change: +2.12%

$CTVA
Wire

RBC Capital Adjusts Corteva Price Target to $97 From $95, Maintains Outperform Rating

Corteva (CTVA) has an average rating of overweight and mean price target of $87.71, according to analysts polled by FactSet.Price: $80.03, Change: $-1.74, Percent Change: -2.13%

$CTVA
Wire

UBS Adjusts Price Target on Corteva to $90 From $88, Maintains Neutral Rating

Corteva (CTVA) has an average rating of overweight and mean price target of $87.71, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $80.60, Change: $-1.16, Percent Change: -1.42%

$CTVA
Wire

BNP Paribas Adjusts Price Target on Corteva to $77 From $74

Corteva (CTVA) has an average rating of overweight and mean price target of $86.33, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $81.41, Change: $-2.49, Percent Change: -2.97%

$CTVA
Research

Research Alert: CFRA Lowers Opinion On Shares Of Corteva, Inc. To Hold From Buy

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We keep our target at $84, 20.1x our 2027 EPS estimate, in line with CVTA's five-year average. After Q1 earnings release, we raise our 2026 EPS view to $4.01 from $3.72 to reflect the Q1 beat. We maintain our 2027 EPS estimate at $4.17. CTVA delivered strong Q1 2026 results today after market close, demonstrating robust operational execution across both business segments, while maintaining momentum toward the planned 2H 2026 separation of the Seed and Crop Protection business. Net sales increased to $4.9B (+11% Y/Y) with organic growth of 7% Y/Y, reflecting broad-based demand for the company's differentiated technology offerings across all geographic regions. Management confirmed the separation remains on track for 2H 2026, with key milestones including Luke Kissam's appointment as New Corteva CEO and the announcement of "Vylor" as the future seed and genetics company name. Yet, with shares up nearly 32% in the last six months, we see limited upside potential at this point and lower our rating to Hold from Buy.

$CTVA
Research

Research Alert: Ctva Delivers Strong Q1 Results, Advances Toward Planned 2h 2026 Separation

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Corteva delivered strong Q1 2026 results with operating EPS of $1.50 significantly exceeding consensus view of $1.18 (+33% Y/Y) and net sales of $4.9B (+11% Y/Y), $270M above expectations. Organic sales growth of 7% Y/Y reflected broad-based demand for differentiated technology offerings despite challenging agricultural conditions. The robust execution demonstrates management's ability to execute the separation strategy from a position of strength, with 6% global volume gains showcasing continued farmer adoption of advanced solutions. Management maintained the 2026 guidance with operating EBITDA of $4.0B-$4.2B and operating EPS of $3.45-$3.70, targeting Q4 2026 for separation completion. The Seed segment delivered exceptional performance with 34.2% operating EBITDA margins (+310 bps Y/Y), while Crop Protection maintained solid momentum with 23.1% margins (+101 bps Y/Y), reinforcing our view that both segments are well positioned for the planned separation with milestones progressing as expected.

$CTVA
Wire

Corteva Q1 Adjusted Earnings, Revenue Rise

Corteva (CTVA) reported Q1 adjusted earnings late Tuesday of $1.50 per diluted share, up from $1.13 a year earlier.Analysts polled by FactSet expected $1.17.Revenue in the three months ended March 31 rose to $4.91 billion from $4.42 billion a year earlier.Analysts surveyed by FactSet expected $4.64 billion.The company expects full-year operating EPS of $3.45 to $3.70. Analysts expect $3.66.Corteva shares fell 2% in after-hours trading.

$CTVA
Wire

Rothschild & Co Redburn Adjusts Corteva Price Target to $90 From $80, Maintains Neutral Rating

Corteva Inc (CTVA) has an average rating of overweight and mean price target of $86.19, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $79.55, Change: $+0.61, Percent Change: +0.77%

$CTVA

Track with the FINWIRES app suite